Q1 Earnings Estimate for HRMY Issued By HC Wainwright

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities researchers at HC Wainwright issued their Q1 2027 earnings estimates for Harmony Biosciences in a report released on Thursday, April 23rd. HC Wainwright analyst P. Trucchio expects that the company will earn $0.90 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.33 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q2 2027 earnings at $1.07 EPS.

A number of other equities analysts also recently commented on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday, December 29th. Truist Financial lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Zacks Research lowered shares of Harmony Biosciences from a “hold” rating to a “strong sell” rating in a report on Thursday, March 26th. Wall Street Zen cut shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, UBS Group reduced their target price on shares of Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Harmony Biosciences currently has an average rating of “Hold” and an average target price of $42.67.

Harmony Biosciences Trading Up 0.3%

HRMY opened at $32.08 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.60 and a quick ratio of 3.58. The company’s 50 day simple moving average is $29.23 and its two-hundred day simple moving average is $32.68. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of 11.84, a price-to-earnings-growth ratio of 0.43 and a beta of 0.89. Harmony Biosciences has a 1-year low of $25.52 and a 1-year high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.38 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The business had revenue of $243.78 million for the quarter, compared to analyst estimates of $240.04 million. During the same quarter in the previous year, the firm posted $0.85 earnings per share. The business’s revenue was up 21.1% compared to the same quarter last year.

Insider Buying and Selling at Harmony Biosciences

In related news, CFO Sandip Kapadia sold 3,746 shares of the firm’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $37.15, for a total transaction of $139,163.90. Following the completion of the sale, the chief financial officer directly owned 24,521 shares of the company’s stock, valued at approximately $910,955.15. This trade represents a 13.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Harmony Biosciences

A number of institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC lifted its holdings in shares of Harmony Biosciences by 109.9% in the 1st quarter. SG Americas Securities LLC now owns 2,018,174 shares of the company’s stock worth $56,529,000 after acquiring an additional 1,056,507 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Harmony Biosciences by 8.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,830,726 shares of the company’s stock valued at $68,507,000 after purchasing an additional 139,145 shares during the last quarter. American Century Companies Inc. raised its position in Harmony Biosciences by 11.2% in the third quarter. American Century Companies Inc. now owns 1,669,565 shares of the company’s stock valued at $46,013,000 after purchasing an additional 168,145 shares during the period. State Street Corp boosted its position in shares of Harmony Biosciences by 0.5% during the fourth quarter. State Street Corp now owns 1,661,850 shares of the company’s stock worth $62,186,000 after buying an additional 8,246 shares during the period. Finally, LSV Asset Management raised its holdings in shares of Harmony Biosciences by 3.9% in the 4th quarter. LSV Asset Management now owns 1,657,093 shares of the company’s stock valued at $62,008,000 after buying an additional 62,200 shares during the period. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.